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OBJECTIVES: To investigate potential drivers of costs and cost savings when as-
sessing the budget impact of insulin administration devices (IADs) in patients with
type 2 diabetes (T2D).METHODS:AMicrosoft Excel®-basedmodel was constructed
to assess the budget impact of new reusable IADs in patients with T2D. The model
captured costs of insulin, IADs, needles, self-monitoring of blood glucose (test
strips and glucometers) and the direct medical costs of a number of diabetes com-
plications (minor and major hypoglycemia, myocardial infarction, stroke, end-
stage renal disease, blindness and amputation). Scenarios were constructed to
assess the budget impact of changes in hypoglycemia rates, compliance and insu-
lin wastage associated with a new IAD. The analyses were performed in a one
million member US healthcare plan from the payer perspective. Future costs were
discounted at 3%per annumand sensitivity analyseswere performed. RESULTS: In
a million member plan with a diabetes prevalence of 7.8% and annual diabetes
incidence of 0.52%, a hypothetical IAD capable of reducing hypoglycemia rates or
insulin wastage was projected to decrease healthcare expenditure over one and
five-year time horizons. Conversely, a hypothetical IAD capable of improving com-
pliance resulted in increased healthcare expenditure, driven by increased insulin
and needle costs. A device that conferred all of these benefits simultaneously was
found to be cost saving in the target population, resulting in a 0.62% decrease in
diabetes-related healthcare expenditure over five years. CONCLUSIONS: An IAD
capable of reducing hypoglycemic event rates and insulin wastage whilst improv-
ing compliance would likely be cost saving overall.
PMD12
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OBJECTIVES: The objective of this analysis was to highlight the differences in gen-
der pain management after a total knee arthroplasty in the United States.
METHODS:We identified 103,600 TKA procedures from the Thomson Reuters Mar-
ketScan® Commercial andMedicare Claim databases from January 1, 2003 through
June 30, 2009. For these procedures, we analyzed 873,237 pharmaceutical claims for
muscle relaxants and analgesics/antipyretics for the 12-month postoperative pe-
riod. The mean direct costs were calculated for each calendar year for gender
cohorts and not inflation-adjusted. Wilcoxon-Mann-Whitney tests were run for
each year to determine statistical significance among the gender cohorts.
RESULTS: During the analysis period, we found statistically significant differences
in pharmaceutical pain management spending between male and female cohorts.
The female cohort spending averaged $464 per patient for the 12-month postoper-
ative period compared to $364 for the male cohort. This represents a 27% differ-
ence. During this same period, the average number of pharmaceutical pain man-
agement claims per TKA decreased for all cohorts but these averages exhibited
convergence in 2008 as spending bymales increased slightly. CONCLUSIONS: Pub-
lished studies have failed to agree on the correlation between gender and postop-
erative pain. A recent postoperative pain study concluded that “gender was not
found to be a consistent predictor as traditionally believed©.” However, our retro-
spective analysis of actual claim data provides a statistically significant correlation
between female gender and increased consumption of postoperativemuscle relax-
ants and analgesics for total knee arthroplasty procedures. These data may help
surgeons provide appropriate postoperative care for their TKA patients. 1Ip, Hui
Yun Vivian, Et. al, Predictors of Postoperative Pain and Analgesic Consumption: A
Qualitative Systematic Review, Anesthesiology, September 2009:11(3)657-677.Mar-
ketScan® is a trademark of Thomson Reuters (Healthcare) Inc.
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POST INGUINAL HERNIA REPAIR PAIN MANAGEMENT COSTS: A STUDY USING
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OBJECTIVES: Several studies have reported on the ability to reduce post-operative
pain following Inguinal Hernia repair by self-fixating mesh. Our study examines
the overall cost increases when post operative pain following Inguinal Hernia Re-
pair is significant enough to be reported by an ICD-9 diagnosis code. METHODS:
The Premier Perspective™ Database (PPD) was used to track hospital costs associ-
atedwith an outpatient Inguinal hernia repair between January, 2008 through June,
2010. ICD-9 diagnosis codeswere used to further identify patient with the presence
of acute or chronic post operative pain. For post discharge painmanagement strat-
egies and costs we sponsored market research with 30 surgeons who perform
Inguinal Hernia repair surgery. Responses were collected to specific pain manage-
ment strategies employed, and average per patient costs when patient reported
pain was mild, moderate, and severe. RESULTS: A total of 51,108 patients under-
going outpatient Inguinal Hernia repair were identified in the PPD during our study
timeframe. An ICD-9 diagnostic code representing acute or chronic pain was pres-
ent in 228 discharges. The mean cost per discharge for patients with diagnosis of
acute/chronic pain was $3,309, compared to $2,910 for patients without the diag-
nostic of pain. Eighty percent of the physicians surveyed reported they would
prescribe pain therapy with a cost of less than $ 100.00. For moderate pain the
breakdown was 70% less than $100.00 and for severe pain 44% indicated the costs
would be less than $100.00. CONCLUSIONS: The management of pain following
Inguinal Hernia repair increase the pre- and post- discharge costs to the hospital,
insurers and patients. In addition, costs appear to increase in relation to the sever-
ity of the pain reported. Inguinal hernia repair techniques which result in reduced
post operative pain such as using self fixating mesh have the potential to reduce
the costs associated with Inguinal Hernia repair.
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OBJECTIVES: Biologic graft implants are used in the repair of complex Incisional/
Ventral hernias when in the surgeon’s judgment the complexity of the hernia
and/or the patient’s risk factors indicate a biologic material provides an opportu-
nity for better outcomes than repair performedwith syntheticmeshmaterials. Our
objective was to examine the average cost per discharge of Incisional/Ventral her-
nia repair when Permacol™ and Strattice™ biological meshes were used.
METHODS: The Premier Perspective™ Database (PPD) was used to track hospital
reported costs associated with patient stays for Incisional/Ventral hernia repair
utilizing Permacol™ and Strattice™ in the 27 months from April, 2008 through
June, 2010. PPD is the largest hospital-based, service-level comparative database in
the USA providing detailed resource utilization and cost data categorized under a
patients’ principal and secondary procedure codes. ICD-9 procedure codes were
used to identify patients with Incisional/Ventral hernia repair. RESULTS: A total of
36,105 patients with a primary procedure code for Incisional/Ventral hernia repair
were identified between April, 2008 through June, 2010. Biologics were used in 4.2%
of these patients. Permacol™was used 135 patients and Strattice™was used in 287
patients. There were no significant differences in patient’s demographics between
the two groups. Mean and median cost per discharge was lower for Permacol™
cases compared to Strattice™ ($19,221 vs. $22,428 formean and $3,163 vs. $5,102 for
median). Cost of “Central Supply” accounted for approximately 50% of the overall
cost in both groups, while “Room and Board” accounted for approximately 22% of
the overall cost. CONCLUSIONS: The mean cost of the biologic implant was re-
ported as 42% higher when Strattice™ was used vs when Permacol™ was used
($6,596 vs. $4,659) in Incisional/Ventral hernia repairs. The mean overall discharge
costs was 17% higher when Strattice™ was used vs Permacol™ ($22,428 vs.
$19,221).
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OBJECTIVES: Estimate the yearly costs attributable to and resulting from the pro-
vision of different self-monitoring of blood glucose (SMBG) regimes vs. no SMBG in
the treatment of patients with type-2 diabetes (T2D) from the Mexican public
health system perspective.METHODS: The individual experience of a patient with
T2D was simulated using a discrete event simulation built in Arena™. Patients
were created with unique, randomly assigned clinical, epidemiologic and demo-
graphic baseline characteristics, cloned 3 times, and sent to each of the SMBG
regimes considered (0, 1, 2 and 3 times daily). Clinical guidelines (ADA, ALAD) were
used to determine diabetic- and complication-specific pharmacologic treatment,
resource utilization and treatment algorithms & goals. Glycosilated hemoglobin
(HbA1c) was the main driver of disease progression, determining initial state, drug
titulation/combinations and insulin dosage. Treatment therapies include lifestyle
modifications alone, oral antidiabetics (OADs) and insulin use. Complication and
acute event development for each SMBG regime was assessed through relative
risks, taken from local published studies. All OADs and insulins were assumed to
be equally effective in reducing HbA1c. T2D-related complications and mortality
were considered. All clinical and cost datawere obtained frompublished literature.
Simulation was run with 16,000 patients for 20 years using a 4.5% annual discount
rate. Per-patient costs for selected years are shown in inflation-adjusted 2010MXP.
RESULTS: 1, 2 and 3 times daily SMBG regimes resulted in lesser costs than no
SMBG after years 1, 3 and 4, respectively. Year 5 accumulated costs for the former
were $114,099, $108,152 and $110,898, and $120,723 for no SMBG. CONCLUSIONS:
SMBG adoption yields better mid- and long-run clinical and economic outcomes
than no SMBG. Potential savings are due to fewer complications and slower disease
progression. Healthcare institutions should adopt SMBG to control HbA1c levels
and reduce the social and economic burden T2D imposes.
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OBJECTIVES: Laparoscopic thoracic procedures have often been associated with
shorter hospitalizations. However, the economic impact of laparoscopic thoracic
procedures compared to open thoracic procedures have not been fully assessed. In
this study, we examined the differences in cost and hospital length of stay for open
versus laparoscopic thoracic procedures in the United States.METHODS: The Pre-
mier Perspective™ Database (PPD) was used to estimate the incidence and costs of
laparoscopic versus open thoracic procedures in the United States. PPD is the larg-
est hospital-based database in the USA providing detailed resource utilization and
cost data. Patients with principal procedure codes for open or laparoscopic proce-
dures between January 1, 2007 through December 31, 2009 were selected. Combi-
nations of ICD-9 diagnosis codes and CPT procedure codes were used to identify
surgical site infections, hemorrhage and blood transfusions. RESULTS: A total of
22,640 patients with a primary procedure code for thoracic procedures were iden-
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tified between January 1, 2007 and December 31, 2009. The surgical approach was
laparoscopic in 57.3%patients, and open in 42.7%patients.Mean cost per discharge
was significantly higher in open thoracic procedures compared to laparoscopic
procedures, $24,995 vs. $19,238, respectively(p0.001). Patients undergoing laparo-
scopic thoracic procedures had a significantly lower rate of surgical site infections
compared to patientswho underwent open procedures (4.8% vs. 5.8%, respectively,
p0.001). There was a significantly higher rate of blood transfusions with patients
undergoing open surgery compared to patients undergoing laparoscopic proce-
dures (13.2% vs. 6.3%, respectively, p0.001). CONCLUSIONS: Laparoscopic tho-
racic procedureswere associatedwith shorter hospital lengths of stay, lower rate of
surgical site infections, hemorrhage, blood transfusion and mortality rates. The
mean costs for laparoscopic procedures were significantly lower than mean costs
for open procedures. These observations highlight the potential cost advantages of
providing thoracic procedures through laparoscopic techniques as a method to
potentially save increasingly scarce healthcare funds for hospitals.
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NON-INSULIN TREATED TYPE-2 DIABETES: RESULTS FROM THE STEP STUDY
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OBJECTIVES: Analyze the differential in selected direct costs of a collaborative
structured blood glucose testing intervention in non-insulin treated patients with
type 2 diabetes mellitus (T2DM) when compared to enhanced usual care (active
control group (ACG)). METHODS: Data was derived from the Structured Testing
Program (STeP) - a 1 year, prospective, cluster-randomized, multicenter study that
examined the utility of a collaborative intervention using structured self-monitor-
ing of blood glucose (SMBG) in 483 poorly-controlled (HbA1c 7.5%) T2DM subjects
compared to the ACG. The structured testing group (STG) used the ACCU-CHEK®
360¢a View 3-day profile tool that facilitates collection and interpretation of 7-point
glucose profiles. From a US payer perspective, direct costs of diabetesmedications,
lab HbA1c tests, physician visits, and blood glucose testing strips associated with
STG were compared with ACG using student t-test at a significance level of 5%.
RESULTS: In the intent-to-treat population, STG showed a significantly greater
HbA1c reduction over 12 months than the ACG (-1.2% vs. 0.9%; 	-0.3%; p0.04).
During the study, STG incurred $180.95 mean PPPY (Pay per Patient Year) total
cost for diabetes medications, but -$173.73 mean PPPY for SMBG test strips, -$5.20
mean PPPY for labHbA1c tests, and -$2.15mean PPPY for physician visits compared
to ACG. There was no significant difference in direct costs between STG and ACG
(p 0.9898). CONCLUSIONS: Use of a collaborative structured testing intervention
improved HbA1c in STG without increasing direct cost. The increased STG medi-
cation cost was offset by a decreased use of blood glucose test strips. As previously
reported, STG subjects performed significantly fewer tests/day than ACG subjects
(mean  0.9 vs. 1.2, p0.0003) over the year. Structured testing, from a 1 year US
payer perspective, is an effective and overall cost-neutral tool for management of
non-insulin treated patients with type 2 diabetes.
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THERAPY VERSUS MULTIPLE DAILY INJECTIONS OF INSULIN IN ADULTS WITH
TYPE 1 DIABETES: EVALUATING A TECHNOLOGY IN EVOLUTION
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OBJECTIVES: Sensor-augmented pump therapy (SAPT) demonstrated a significant
reduction in HbA1c levels in type 1 diabetes patients compared to multiple daily
injections of insulin (MDI) in a recent randomized trial. We analyzed the data on
medical resource use collected within the trial and evaluated the long-term cost-
effectiveness of SAPT versusMDI in adultswith type 1 diabetes from the healthcare
systemperspective.METHODS:Wecombined estimates derived from the trial data
and the medical literature to populate the previously-validated CORE Diabetes
Model, which includes a series of Markov constructs that simulate the progression
of diabetes-related complications. During the 52-week trial period, SAPT patients
were provided insulin pumps and 3-day sensors. Electronic records indicated that
sensors were worn only by patients 65% of the time. The incremental reduction in
mean glycated hemoglobin was 0.6 percentage points in patients randomized to
SAPT relative to MDI. RESULTS: Among the 329 adults (19-70 years), mean age was
41 years andmeanduration of diabeteswas 20 years. Total treatment costs over the
52-week follow-up period were estimated at $10,760 for SAPT patients and $5,072
for MDI patients (2010 US$). Discounted (3% per year) lifetime estimates of direct
medical costs and QALYs were $253,493 and 10.794 for SAPT patients and $167,170
and 10.418 for MDI patients. The corresponding ICER was $229,675 per QALY (95%
CI: 139,071 to 720,865). Sensitivity analyses revealed that evolving technologies
could improve the cost-effectiveness of SAPT. With a 6-day sensor, the ICER de-
creased to $168,104 per QALY. Upon development of a 6-day sensor that requires
only one test strip per replacement for calibration, the ICER would drop to
$72,417/QALY. CONCLUSIONS: Our base-case findings revealed that the current
SAPT technology is not economically attractive. However, with technological ad-
vances currently in process, the cost-effectiveness of the SAPT could significantly
improve.
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OBJECTIVES: To assess the cost-effectiveness of epidermal growth factor receptor
(EGFR) gene mutation testing for guiding the application of gefitinib as first-line
therapy in patients with advanced non-small cell lung cancer (NSCLC) living in
Ontario. METHODS: A decision analytic model was developed to compare EGFR
gene mutation testing strategy versus no testing strategy in patients with ad-
vanced NSCLC. Under the testing strategy, patients tested positive for mutation
would receive gefitinib as first-line therapy. Under no testing strategy, patients
would receive conventional chemotherapy as first-line therapy. Probability vari-
ables were estimated through literature review. Utility variables were estimated
from a multivariate linear regression analysis taking into account of the clinical
responses and side-effects associated with treatment for NSCLC. Cost variables
were based on two Ontario cost studies for NSCLC. Both benefits and costs were
discounted at 5% per annum. RESULTS: Compared to no testing strategy, the in-
cremental cost-effectiveness ratio for EGFR gene mutation testing was $46,021 per
life year or $81,071 per quality adjusted life year (QALY). The cost-effectiveness of
EGFR gene mutation testing was sensitive to the cost and efficacy of gefitinib. The
budget impact analysis projected that EGFR gene mutation testing would cost On-
tario health care system $4.6M, $7.0M, $7.9M, $8.1M, and $8.1M more a year in the
next five years. CONCLUSIONS: EGFR gene mutation testing would not be cost-
effective in patients with advanced NSCLC in Ontario until willingness-to-pay was
above $81,000 per QALY. The efficacy and cost of gefitinib significantly affected the
cost-effectiveness of EGFR gene mutation testing.
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OBJECTIVES: A new prostate cancer detection index was developed as a combina-
tion of serum prostate-specific antigen (PSA), free PSA, and a PSA precursor form
[-2]proPSA to calculate the probability of prostate cancer and used as a diagnostic
aid for men age 50 years or older with PSA 4-10 ng/mL and nonsuspicious digital
rectal exam. The index has demonstrated improved specificity for detecting pros-
tate cancer over PSA test alone in clinical trials. The current study evaluated the
cost-effectiveness of early prostate cancer detection with the index adding to PSA
compared with PSA test alone from the U.S. societal perspective. METHODS: A
Markov model with probabilistic sensitivity analysis was constructed to estimate
the costs and health state utilities of prostate cancer detection and consequent
treatment for the annual prostate cancer screening of themale fromage 50 through
75 years. The transition probabilities, health state utilities, and prostate cancer
treatment costs were derived from the published literature. The diagnostic perfor-
mance of the index was obtained from a multi-center simulation study of the
index. Diagnostic related costs were obtained from the 2009 Medicare Fee Sched-
ule. Expected costs and effects were discounted at 3%. RESULTS: Over 25 annual
screening cycles, the strategy of the index adding to PSA dominated the PSA test
alone for prostate cancer detection. It was estimated to save $234, with an expected
gain of 0.02 quality adjusted life years (QALYs). The probability of the index test
being cost-effective is approximately 85% at the range of $50,000/QALY to $200,000/
QALY willingness to pay. Model results are most influenced by screening starting
age, discount rate, and biopsy utilization rates. CONCLUSIONS: The index as an aid
adding to PSA test may be an important strategy for prostate cancer detection as
compared to using PSA alone testing.
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OBJECTIVES: To assess the cost-effectiveness of CyberKnife (CK) compared to sur-
gery and radiation therapies for the treatment of localized prostate cancer (PC)
from societal and third party payer perspectives.METHODS: A Markov model was
used to compare treatmentwith CK, intensitymodulated radiation therapy (IMRT),
proton therapy (PT), and surgery, in 60-year-old patients. Themodel reflected both
procedure-relatedmortality and the comparative risks of long-term toxicity among
survivors, defined as adverse events grade 2 on Radiation Therapy Oncology
Group scale occurring at least 12 months following treatment: genitourinary (GU);
gastrointestinal (GI); and/or sexual dysfunction (SD). In the absence of evidence on
comparative effectiveness we assumed that long-term disease control andmortal-
ity would not differ across treatments. Toxicity probabilities were derived using
meta-analytical techniques. Utilities for adverse events were derived from a pub-
lished survey of PC patients using standard gamble technique. Model-projected
expected lifetime costs and quality adjusted life years (QALYs) for each treatment
were used to calculate the incremental cost-effectiveness of CK versus compara-
tors. The societal perspective included productivity costs owing to time spent in
treatment. Extensive sensitivity analyses were conducted. RESULTS: From a pay-
er’s perspective, surgery was least expensive followed by CK, IMRT and PT. How-
ever, CK patients had higher expected QALYs (9.54) than other options (9.08-9.49).
Incremental cost per QALY gained for CK versus surgery was $13,100/QALY. Com-
pared to IMRT and PT, CK was less costly with higher QALYs (dominant). From a
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